LivaNova Provides Update on RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients

Contributed by: Business Wire

Logo

Tags

Mental Health

Research

Clinical Trials

Biotechnology

Other Health

Health

Pharmaceutical

General Health

Science

LivaNova PLC

More Like This

LivaNova Announces OSPREY Clinical Study Meets Primary Safety and Efficacy Endpoints

LivaNova Announces a Positive Predictive Outcome of Trial Success in its OSPREY Clinical Study for Moderate to Severe Obstructive Sleep Apnea

LivaNova Reports Second-Quarter 2024 Results

PR Newswire associated0

Neurolief Announces Breakthrough Results from Pivotal Clinical Trial of Brain Neuromodulation System for Treating Major Depressive Disorder

LivaNova to Wind Down Advanced Circulatory Support Business Unit

CYB003 (12mg dose) demonstrated a rapid and statistically significant reduction in symptoms of depression at three weeks after a single dose, meeting the primary efficacy endpoint (Graphic: Business Wire)

Cybin Announces Unprecedented Positive Phase 2 Interim Data for CYB003 in Major Depressive Disorder Meeting Primary Efficacy Endpoint with Rapid and Significant Improvements in Depression Symptoms After Single Dose

Denovo Biopharma Announces a Major Breakthrough in Treatment‑Resistant Depression with Precision Medicine

LivaNova to Present at the Goldman Sachs Healthcare Conference